85 related articles for article (PubMed ID: 29851442)
1. Impact of formulary restrictions on medication intensification in diabetes treatment.
Stuart BC; Slejko JF; Rueda JD; Cooke CE; Shen X; Roberto P; Ciarametaro M; Dubois R
Am J Manag Care; 2018 May; 24(5):239-246. PubMed ID: 29851442
[TBL] [Abstract][Full Text] [Related]
2. Impact of formulary restrictions on medication use and costs.
Shen X; Stuart BC; Powers CA; Tom SE; Magder LS; Perfetto EM
Am J Manag Care; 2017 Aug; 23(8):e265-e274. PubMed ID: 29087150
[TBL] [Abstract][Full Text] [Related]
3. Does the offer of free prescriptions increase generic prescribing?
Stuart B; Hendrick F; Dougherty JS; Xu J
Am J Manag Care; 2017 Jun; 23(6):e193-e201. PubMed ID: 28817295
[TBL] [Abstract][Full Text] [Related]
4. Healthcare Costs Among Adults with Type 2 Diabetes Initiating DPP-4 Inhibitors.
Farr AM; Sheehan JJ; Brouillette M; Smith DM; Johnston SS; Kalsekar I
Adv Ther; 2016 Jan; 33(1):68-81. PubMed ID: 26724938
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
[TBL] [Abstract][Full Text] [Related]
6. How Low-Income Subsidy Recipients Respond to Medicare Part D Cost Sharing.
Stuart B; Hendrick FB; Xu J; Dougherty JS
Health Serv Res; 2017 Jun; 52(3):1185-1206. PubMed ID: 27324201
[TBL] [Abstract][Full Text] [Related]
7. Placement of selected new FDA-approved drugs in Medicare Part D formularies, 2009-2013.
Stuart BC; Tom SE; Choi M; Johnson A; Sun K; Qato D; Obi EN; Zacker C; Park Y; Arcona S
Am J Manag Care; 2018 Jun; 24(6):e175-e182. PubMed ID: 29939507
[TBL] [Abstract][Full Text] [Related]
8. Brand-name prescription drug use among Veterans Affairs and Medicare Part D patients with diabetes: a national cohort comparison.
Gellad WF; Donohue JM; Zhao X; Mor MK; Thorpe CT; Smith J; Good CB; Fine MJ; Morden NE
Ann Intern Med; 2013 Jul; 159(2):105-14. PubMed ID: 23752663
[TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
[TBL] [Abstract][Full Text] [Related]
10. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
11. Medicare formulary restrictions for glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors used in type 2 diabetes mellitus: 2019-2023.
Wisniewski B; Smith E; Kaur J; Sherling C; Vanapalli S; Lussier M
J Manag Care Spec Pharm; 2024 Jan; 30(1):34-42. PubMed ID: 38153863
[TBL] [Abstract][Full Text] [Related]
12. Medicare Part D formulary coverage since program inception: are beneficiaries choosing wisely?
Jackson EA; Axelsen KJ
Am J Manag Care; 2008 Nov; 14(11 Suppl):SP29-35. PubMed ID: 18991478
[TBL] [Abstract][Full Text] [Related]
13. Do Restrictions on Antipsychotic Use Differ Between Medicare Part D Stand-Alone Versus Medicare Advantage Plans?
Chou J; Brandt NJ; Loh FE; Stuart B
Consult Pharm; 2017 Feb; 32(2):109-118. PubMed ID: 28569663
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Coverage Restrictions on Antipsychotic Utilization Among Low-Income Medicare Part D Enrollees.
Roberto PN; Brandt N; Onukwugha E; Perfetto E; Powers C; Stuart B
Adm Policy Ment Health; 2017 Nov; 44(6):943-954. PubMed ID: 28660370
[TBL] [Abstract][Full Text] [Related]
15. Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program.
Luo J; Feldman R; Rothenberger SD; Hernandez I; Gellad WF
JAMA Netw Open; 2020 Oct; 3(10):e2020969. PubMed ID: 33057641
[TBL] [Abstract][Full Text] [Related]
16. [Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact].
Sicras-Mainar A; Navarro-Artieda R
Rev Peru Med Exp Salud Publica; 2014; 31(4):626-34. PubMed ID: 25597711
[TBL] [Abstract][Full Text] [Related]
17. Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.
Driessen JH; van den Bergh JP; van Onzenoort HA; Henry RM; Leufkens HG; de Vries F
Diabetes Obes Metab; 2017 Mar; 19(3):421-428. PubMed ID: 27943565
[TBL] [Abstract][Full Text] [Related]
18. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
19. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
[TBL] [Abstract][Full Text] [Related]
20. Estimation of Medicare Part D Spending on Insulin for Patients With Diabetes Using Negotiated Prices and a Defined Formulary.
Feldman WB; Rome BN; Lehmann LS; Kesselheim AS
JAMA Intern Med; 2020 Apr; 180(4):597-601. PubMed ID: 32011624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
